Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for relapsed and refractory multiple myeloma after 3 or more treatments:
- Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (2024) NICE technology appraisal guidance 1023
- Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (2024) NICE technology appraisal guidance 1015
This page was last updated: